Vivos Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vivos Therapeutics (VVOS).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$4Upside to Avg. PT+2847.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 4, 2026	Ascendiant Capital	Lucas Ward	PT Raise	Buy	$3→$3
Apr 22, 2026	Ascendiant Capital	Lucas Ward	PT Cut	Buy	$6→$3
Apr 17, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$7→$3
Dec 3, 2025	Ascendiant Capital	Lucas Ward	PT Cut	Buy	$7→$6
Nov 17, 2025	HC Wainwright & Co.	Yi Chen	Initiate	Buy	$7
Sep 9, 2025	Ascendiant Capital	Lucas Ward	PT Raise	Buy	$6→$7
Apr 15, 2025	Ascendiant Capital	Lucas Ward	PT Cut	Buy	$7→$6
Nov 20, 2024	Ascendiant Capital	Lucas Ward	Maintained	Buy	$7
Nov 19, 2024	Alliance Global Partners	Scott Henry	PT Cut	Buy	$8→$6
Aug 20, 2024	Ascendiant Capital	Lucas Ward	PT Raise	Buy	$6→$7

Analyst Ratings News

CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday

Top Wall Street analysts updated ratings on CRWD, OLLI, XPO, SHAK, UNH, PVH, VVOS, and SYRE. See analyst ratings page for full details.

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $3 to $3.1.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $5.5 to $3.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $7 to $2.5.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $6.5 to $5.5.

Benzinga Newsdesk

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

Vivos Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Vivos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

PRO
HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

People Also Watch

People Also Watch

Vivos Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Vivos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday

PROAscendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

PROAscendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

PROHC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

PROAscendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

PRO
HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5